Back to top
more

REGENXBIO (RGNX)

(Delayed Data from NSDQ)

$16.19 USD

16.19
305,658

+0.13 (0.81%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $16.19 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for RGNX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for REGENXBIO Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 275 365 457 476 296
Receivables 25 28 32 43 38
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 35 23 29 12 11
Total Current Assets 335 416 519 531 345
Net Property & Equipment 132 142 132 56 29
Investments & Advances 39 201 392 47 104
Other Non-Current Assets 1 2 2 3 4
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 7 8 8 7 6
Total Assets 574 833 1,114 708 498
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 23 27 11 11 6
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 50 47 76 49 25
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 51 50 41 19 0
Total Current Liabilities 130 130 130 81 34
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 4 3
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 50 98 134 175 2
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 262 317 350 330 48
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,021 973 928 667 628
Retained Earnings -705 -442 -161 -289 -178
Other Equity -4 -15 -3 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 312 516 764 378 450
Total Liabilities & Shareholder's Equity 574 833 1,114 708 498
Total Common Equity 312 516 764 378 450
Shares Outstanding 43.90 43.20 42.70 37.40 36.80
Book Value Per Share 7.10 11.95 17.90 10.10 12.23

Fiscal Year End for REGENXBIO Inc falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 275 302 320 332
Receivables NA 25 28 21 19
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 35 36 37 39
Total Current Assets NA 335 366 379 389
Net Property & Equipment NA 132 136 139 142
Investments & Advances NA 39 63 95 142
Other Non-Current Assets NA 1 1 1 1
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 7 7 6 10
Total Assets NA 574 634 682 748
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 23 22 12 23
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 50 46 51 32
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 51 53 49 51
Total Current Liabilities NA 130 127 118 112
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 59 73 83
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 262 271 277 283
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 1,021 1,013 996 985
Retained Earnings NA -705 -642 -580 -508
Other Equity NA -4 -7 -10 -12
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 312 363 406 465
Total Liabilities & Shareholder's Equity NA 574 634 682 748
Total Common Equity 0 312 363 406 465
Shares Outstanding 49.00 43.90 43.90 43.90 43.40
Book Value Per Share 0.00 7.10 8.27 9.25 10.72